Submitted by Nancy Lapid (Reuters) -Novo Nordisk and Eli Lilly’s most popular weight loss medication should be the first medicines to treat doctors to treat obesity and its complications, the European Medical Association advised Thursday. Semaglutid, the active Novo Wegovy and Ozempic and Tyzepatide, sold as Zepbound and Mounjar, Lilly, are so effective that they … Read more
The GoodRX (GDRX) on Monday joins the GLP-1 action with a report that it will start selling both Novo Nordisk (NGO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss at a net price of $ 499 per month. Partnership occurs when remote health and digital health platforms are increasingly regarded as ways to … Read more
HIMS & JI (HIMS) shares fell almost 35% on Monday after Novo Nordisk (NGO) announced that it is completing cooperation to produce his BlockBuster weight loss drug Wegovy, available on the Him Telehealth platform. Novo Nordisk said Hims & He had violated law and continued to sell Copycat Semaglutide, the main ingredient of Wegovy, along … Read more
The Him & Herss (HIMS) shares on Monday in early trading fell by about 30% after Novo Nordisk (NGO) announced that it is completing cooperation to produce its BlockBuster weight loss drug Wegovy, available in HIMS remote health platform. Novo Nordisk said Hims & He had violated law and continued to sell Copycat Semaglutide, the … Read more